Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Cytovir CMV for cytomegalovirus infection in patients undergoing allogeneic haematopoietic stem cell transplantation. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2016 Authors' objectives Cytomegalovirus (CMV) is a common viral infection which is carried by around 50% of the population and causes no harm to healthy people. However, for people undergoing blood or bone marrow transplantation it can cause serious complications due to their reduced immunity to infection.
Cytovir CMV is a new treatment that aims to prevent and treat CMV infection following blood or marrow transplantation. It is made up of immune cells that specifically attack CMV and it is administered by intravenous infusion.
Cytovir CMV is currently being studied to see how well it works and whether it is safe to use in people who have undergone blood or marrow transplantation. It is already available to specialist transplant centres in the UK. Indexing Status Subject indexing assigned by CRD MeSH Cytomegalovirus Infections; Hematopoietic Stem Cell Transplantation; Humans; Transplantation, Homologous Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NIHR Horizon Scanning Research&Intelligence Centre, University of Birmingham, Institute of Applied Health Research, Public Health building, Edgbaston, Birmingham B15 2TT
Tel: 0121 414 9077 Email: nihrhsc@contacts.bham.ac.uk AccessionNumber 32016000428 Date abstract record published 04/03/2016 |